ADIL
Adial Pharmaceuticals, Inc. · Healthcare
Insiders bought $98K of Adial Pharmaceuticals, Inc. in the last 12 months
1 insider bought on 2 days.
ADIL over the last year
Largest buyers, last 12 months
ADIL after insider buys
3 months after each buy, from the first price a copier could get.
1 buy has 3 months of prices so far. A record shows here at 3.
Every filing
10 insider filings since 2019, newest first
Coastlands Capital LP · 10% owner
Coastlands Capital LP · 10% owner
James W. Newman Jr. · Director
William B. Stilley III · CEO and 10% owner
Bankole A. Johnson · Chief Medical Officer
Bankole A. Johnson · Chief Medical Officer
James W. Newman Jr. · Director
William B. Stilley III · CEO and 10% owner
Bankole A. Johnson · Chief Medical Officer and 10% owner
Bankole A. Johnson · Chief Medical Officer and 10% owner
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.